![Evolution of HR+/HER2- breast cancer during exposure to neoadjuvant chemotherapy and endocrine treatment](https://oncodaily.com/pub/uploads/2024/07/fran-e1719938715362.png)
Photo taken from Francesco Schettini/X
Jul 4, 2024, 14:15
Evolution of HR+/HER2- breast cancer during exposure to neoadjuvant chemotherapy and endocrine treatment
ESMO Open shared a post on X:
“Hot off the press: Francesco Schettini et al. analyze the clinical and biological evolution of HR+/HER2- breast cancer during exposure to neoadjuvant chemotherapy and endocrine treatment. ”
Proceed to the article.
Source: ESMO Open/X
Aug 16, 2024, 14:30